See more : CME Group Inc. (0HR2.L) Income Statement Analysis – Financial Results
Complete financial analysis of Verrica Pharmaceuticals Inc. (VRCA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Verrica Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Flight Centre Travel Group Limited (FLT.AX) Income Statement Analysis – Financial Results
- Auri, Inc. (AURI) Income Statement Analysis – Financial Results
- Dong Yang Piston Co., Ltd. (092780.KS) Income Statement Analysis – Financial Results
- SStartrade Tech, Inc. (SSTT) Income Statement Analysis – Financial Results
- The Hain Celestial Group, Inc. (0J2I.L) Income Statement Analysis – Financial Results
Verrica Pharmaceuticals Inc. (VRCA)
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.12M | 9.03M | 12.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 746.00K | 725.00K | 472.00K | 229.00K | 257.20K | 20.29K | 0.00 | 0.00 |
| Gross Profit | 4.38M | 8.31M | 11.53M | -229.00K | -257.20K | -20.29K | 0.00 | 0.00 |
| Gross Profit Ratio | 85.44% | 91.97% | 96.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.30M | 12.20M | 15.93M | 15.67M | 15.44M | 12.83M | 3.73M | 1.71M |
| General & Administrative | 0.00 | 17.41M | 26.98M | 24.51M | 14.64M | 9.05M | 727.00K | 204.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 47.31M | 17.41M | 26.98M | 24.51M | 14.64M | 9.05M | 727.00K | 204.00K |
| Other Expenses | 2.54M | -58.00K | 0.00 | -1.00K | 1.87M | -1.00K | 0.00 | 0.00 |
| Operating Expenses | 70.14M | 29.60M | 42.91M | 40.18M | 30.08M | 21.88M | 4.46M | 1.91M |
| Cost & Expenses | 70.88M | 30.33M | 42.91M | 40.18M | 30.08M | 21.88M | 4.46M | 1.91M |
| Interest Income | 2.74M | 476.00K | 123.00K | 521.00K | 1.88M | 1.23M | 0.00 | 0.00 |
| Interest Expense | 3.96M | 2.17M | 4.30M | 3.03M | 0.00 | 0.00 | 2.00K | 0.00 |
| Depreciation & Amortization | 836.00K | 718.00K | 472.00K | 229.00K | 257.20K | 20.29K | 4.46M | 1.91M |
| EBITDA | -62.20M | -21.60M | -30.31M | -39.43M | -30.08M | -20.63M | -4.46M | -1.91M |
| EBITDA Ratio | -1,213.84% | -231.16% | -256.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -65.76M | -21.30M | -30.91M | -40.18M | -30.08M | -21.88M | -4.46M | -1.91M |
| Operating Income Ratio | -1,283.35% | -235.78% | -257.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.24M | -3.19M | -4.17M | -2.51M | 1.87M | 1.23M | -2.00K | 0.00 |
| Income Before Tax | -67.00M | -24.49M | -35.08M | -42.69M | -28.21M | -20.65M | -4.46M | -1.91M |
| Income Before Tax Ratio | -1,307.47% | -271.11% | -292.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.19M | 3.82M | 2.80M | -257.00K | 1.23M | -4.46M | -1.91M |
| Net Income | -67.00M | -27.68M | -38.90M | -45.50M | -27.95M | -20.65M | -4.46M | -1.91M |
| Net Income Ratio | -1,307.47% | -306.44% | -324.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.48 | -0.81 | -1.44 | -1.82 | -1.12 | -1.41 | -0.22 | -0.10 |
| EPS Diluted | -1.48 | -0.81 | -1.44 | -1.82 | -1.12 | -1.41 | -0.22 | -0.10 |
| Weighted Avg Shares Out | 45.34M | 34.16M | 27.04M | 25.00M | 24.90M | 14.66M | 19.95M | 19.95M |
| Weighted Avg Shares Out (Dil) | 45.34M | 34.16M | 27.04M | 25.00M | 24.90M | 14.66M | 19.95M | 19.95M |
Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum by Torii Pharmaceutical Co., Ltd. in Japan
The Company earns $8 Million Phase 3 Milestone Payment
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Verrica Investors of a Lead Plaintiff Deadline of August 5, 2022
NEW YORK , Aug. 1, 2022 /PRNewswire/ -- Attention Verrica Pharmaceuticals, Inc. ("Verrica") (NASDAQ: VRCA) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between May 28, 2021...
VRCA INVESTOR NOTICE: ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Verrica Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important August 5 Deadline in Securities Class Action - VRCA
NEW YORK , July 30, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) between May 28, 2021 and May 24, 2022, both dates inclusive...
ROSEN, Leading Investor Counsel, Encourages Verrica Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important August 5 Deadline in Securities Class Action - VRCA
New York, New York--(Newsfile Corp. - July 28, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) between May 28, 2021 and May 24, 2022, both...
Verrica Class Action: Levi & Korsinsky Reminds Verrica Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2022 - VRCA
New York, New York--(Newsfile Corp. - July 27, 2022) - Levi & Korsinsky, LLP notifies investors in Verrica Pharmaceuticals, Inc. ("Verrica" or the "Company") (NASDAQ: VRCA) of a class action securities lawsuit.The lawsuit on behalf of Verrica investors has been...
ROSEN, National Trial Lawyers, Encourages Verrica Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important August 5 Deadline in Securities Class Action - VRCA
New York, New York--(Newsfile Corp. - July 27, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) between May 28, 2021 and May 24, 2022, both...
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - July 25, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ: VRCA) for violations of §§10(b)...
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Verrica Pharmaceuticals Inc. Investors With Losses to Secure Counsel Before Important August 5 Deadline in Securities Class Action - VRCA
New York, New York--(Newsfile Corp. - July 24, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) between May 28, 2021 and May 24, 2022, both...
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Verrica Pharmaceuticals Inc. Investors to Secure Counsel Before Important August 5 Deadline in Securities Class Action - VRCA
NEW YORK , July 23, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) between May 28, 2021 and May 24, 2022, both dates inclusive...
VRCA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 5, 2022 in the Class Action Filed on Behalf of Verrica Pharmaceuticals, Inc. Limited Shareholders
New York, New York--(Newsfile Corp. - July 22, 2022) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Verrica Pharmaceuticals, Inc. (NASDAQ: VRCA) alleging that the Company violated federal securities...
Source: https://incomestatements.info
Category: Stock Reports